Physician profile
Robert D Rozner
NPI 1851346944
$3,361.20
in general payments reported to CMS, 2019-2025
37 companies · $689 in 2025
The $689 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,229 · 2020: $508 · 2021: $113 · 2022: $33.68 · 2023: $231 · 2024: $557 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,477.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $571.54 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $384.25 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $303.40 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $295.93 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Phathom Pharmaceuticals, INC. | $237.55 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $185.33 | 2019-2025 | Trelegy Ellipta |
| Allergan, INC. | $167.12 | 2019-2020 | |
| Pfizer INC. | $129.47 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.79 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $96.75 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.47 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.95 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $61.30 | 2019-2020 | |
| Lilly USA, LLC | $60.36 | 2019-2024 | Zepbound, Jardiance, Mounjaro |
| Exact Sciences Corporation | $58.91 | 2025 | Cologuard Collection Kit |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $56.44 | 2019-2020 | |
| Shire North American Group INC | $50.21 | 2019 | |
| Sanofi-Aventis U.S. LLC | $43.45 | 2019 | |
| Janssen Biotech, INC. | $33.67 | 2019 | |
| Horizon Therapeutics Plc | $32.86 | 2021-2022 | |
| Seqirus USA INC | $25.44 | 2025 | Fluad, Flucelvax |
| Sanofi Pasteur INC. | $25.32 | 2019 | |
| Phadia US INC. | $24.60 | 2019-2020 | |
| Axsome Therapeutics, INC. | $23.70 | 2025 | Symbravo |
| Arbor Pharmaceuticals, INC. | $23.22 | 2019 | |
| Orthogenrx INC. | $23.12 | 2021 | |
| Astellas Pharma US INC | $22.97 | 2019-2020 | |
| Abbott Laboratories | $22.95 | 2023 | Freestyle Libre 3 |
| Depuy Synthes Sales INC. | $18.85 | 2019 | |
| Genentech USA, INC. | $18.17 | 2019 | |
| Romark Laboratories, Lc | $17.16 | 2019 | |
| Medtronic USA, INC. | $17.15 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.99 | 2024 | Caplyta |
| Medtronic Vascular, INC. | $15.57 | 2020 | |
| Assertio Therapeutics, INC. | $13.63 | 2019 | |
| Currax Pharmaceuticals LLC | $13.42 | 2024 | Contrave, Onzetra Xsail |
| Hikma Pharmaceuticals USA | $13.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rozner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.